Article

Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells

2014-05-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ff024b86-9b09-55d5-9956-1eff3ad9af64
DOI: 10.1093/protein/gzu014
PMCID: PMC4274346

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cellsDOI 10.1093/protein/gzu014Read

Trastuzumab-induced cardiotoxicity: is it a personalized risk?Semantic proximity Read

Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTOSemantic proximity Read

Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes.Semantic proximity Read

Herceptin and the Heart — A Molecular Modifier of Cardiac FailureSemantic proximity Read

Small molecule-induced ERBB4 activation to treat heart failureSemantic proximity Read

Bioactivity of Recombinant Humanized Monoclonal Antibody Against HER2 and Its Mechanism of Action on Ovarian CancerSemantic proximity Read

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsSemantic proximity Read

A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancerSemantic proximity Read

Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cellsSemantic proximity Read

A recombinant fragment antigen-binding (Fab) of trastuzumab displays low cytotoxic profile in adult human cardiomyocytes: first evidence and the key implication of FcγRIIA receptorSemantic proximity Read

Adjuvant Weekly Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer without Risk Factors of Cardiotoxicity. Possibility of Omitting Cardiac Monitoring during Treatment.Semantic proximity Read

Targeted delivery of therapeutic agents to the heartSemantic proximity Read